PRKAR2B plays an oncogenic role in the castration-resistant prostate cancer

Jianjun Sha; Wei Xue; Baijun Dong; Jiahua Pan; Xiaorong WU; Dong Li; Dongming Liu; Yiran Huang

doi:10.18632/oncotarget.14044

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

PRKAR2B plays an oncogenic role in the castration-resistant prostate cancer

Jianjun Sha, Wei Xue, Baijun Dong, Jiahua Pan, Xiaorong WU, Dong Li, Dongming Liu and Yiran Huang _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:6114-6129. https://doi.org/10.18632/oncotarget.14044

Metrics: PDF 2443 views | HTML 2722 views | ?

Abstract

Jianjun Sha1,2,*, Wei Xue1,*, Baijun Dong1, Jiahua Pan1, Xiaorong WU1, Dong Li1, Dongming Liu1, Yiran Huang1,2

1Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

2School of Biomedical Engineering, Shanghai Jiaotong University, Shanghai, People’s Republic of China

*Co-first authors

Correspondence to:

Yiran Huang, email: [email protected]

Keywords: PRKAR2B, castration resistant, prostate cancer, CRPC, cell cycle

Received: July 11, 2016 Accepted: December 13, 2016 Published: December 20, 2016

ABSTRACT

Castration-resistant prostate cancer (CRPC) is an advanced form of prostate cancer. Despite some progresses have been made, the mechanism of CRPC development is still largely unknown, including the genes involved in its development have not been well defined. Here, we identifiedPRKAR2B to be a gene over-expressingin castration-resistant prostate cancer by analyzing the different online databases. Followed functional validation experiments showed that PRKAR2B promoted CRPC cell proliferation and invasion, and inhibited CRPC cell apoptosis. Whole genome transcriptome and GO enrichment analyses of the knock-down of PRKAR2B in CRPC cells showed that PRKAR2B mainly accelerated cell cycle biological process and modulated multiple cell cycle genes, such as CCNB1, MCM2, PLK1 and AURKB. Our study firstly identified PRKAR2B as a novel oncogenic gene involved in CRPC development and suggested it is a promising target for the future investigation and the treatment of CRPC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14044

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

PRKAR2B plays an oncogenic role in the castration-resistant prostate cancer

Abstract